培美曲塞联合顺铂治疗晚期复治性非小细胞肺癌90例临床观察

摘要

Objective:To study the pemetrexed concomitant cisplatin sex treatment of advanced non-small cell lung cancer (NSCLC) clinical effect. Methods:The 90 cases of patients with NSCLC sex late treat all use pemetrexed combined cisplatin treatment.Results:90 cases of patients cured by the pemetrexed combined cisplatin treatment of the total effective rate was 30.00%, clinical benefit rate was 81.11%. Followed for 5 years, 1-year survival was 58.89%, the 3 year survival rate 28.89%and 11.11%at 5 years. One of the highest rates of adverse reaction to occur leucocyte reduce 71 cases (78.88%) than the other side reaction, the difference was statistically significant (p<0.05), followed by nausea and vomiting (56.67%). The symptomatic treatment, all side reaction are improved, all did not influence continue chemotherapy. Conclusion:For the first line therapy for patients with advanced NSCLC failure, the pemetrexed and cisplatin combination chemotherapy regimens is one of the ideal treatment.%目的：探讨培美曲塞联合顺铂治疗晚期复治性非小细胞肺癌(NSCLC)的临床效果。方法：对本院90例晚期复治性NSCLC患者均采用培美曲塞联合顺铂治疗。结果：90例患者经培美曲塞联合顺铂治疗的总有效率为30.00%,临床获益率为81.11%。随访5年,1年生存率为58.89%,3年生存率为28.89%、5年生存率为11.11%。毒副反应发生率最高的为发生白细胞降低71例(78.88%)明显高于其他毒副反应,差别有统计学意义(p＜0.05),其次为恶心呕吐(56.67%)。经对症处理后,均毒副反应均改善,均未影响继续化疗。结论：对于一线治疗失败的晚期NSCLC患者来说,采用培美曲塞与顺铂联合化疗方案是理想的治疗方法之一。